Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
J Cutan Med Surg. 2024 Sep-Oct;28(5):481-485. doi: 10.1177/12034754241266125. Epub 2024 Jul 31.
The use of cannabis and cannabis-related products among patients with hidradenitis suppurativa (HS) is increasing globally. Given the potential anti-inflammatory, therapeutic, and pain management benefits of cannabis-related products, we reviewed primary literature to evaluate the prevalence and possible purpose for cannabis use among patients with HS and to provide recommendations to patients and physicians. A narrative review of original studies was conducted using Embase and Ovid Medline databases. The search strategy was confirmed by a librarian and conducted on September 1, 2023, using a detailed list of subject headings and keywords tailored to cannabis, cannabis-related products, HS, and both adult and pediatric populations. Among 43 identified studies, 6 met the eligibility criteria and encompassed 34,435 patients. Patients were mostly female, and studies were conducted across the United States, Canada, and France. Findings show higher cannabis use among HS patients, demonstrating efficacy in pain management, sleep, anxiety relief, itch relief, and improved quality of life. Cannabis may play a role in analgesia, improved quality of life, pain, itch, and overall mental health in patients with HS and healthcare providers including dermatologists should increase their familiarity in appropriate use of cannabis-related products.
全球范围内，患有化脓性汗腺炎（HS）的患者对大麻和大麻类产品的使用正在增加。鉴于大麻类产品具有潜在的抗炎、治疗和疼痛管理益处，我们回顾了主要文献，以评估 HS 患者使用大麻的流行情况和可能的用途，并为患者和医生提供建议。我们使用 Embase 和 Ovid Medline 数据库对原始研究进行了叙述性综述。检索策略由一名图书管理员确认，并于 2023 年 9 月 1 日使用针对大麻、大麻类产品、HS 以及成人和儿科人群的详细主题词和关键字列表进行。在确定的 43 项研究中，有 6 项符合纳入标准，共纳入 34435 名患者。患者主要为女性，研究在美国、加拿大和法国进行。研究结果表明，HS 患者中大麻的使用率更高，在疼痛管理、睡眠、焦虑缓解、瘙痒缓解和生活质量改善方面显示出疗效。大麻可能在 HS 患者的镇痛、改善生活质量、疼痛、瘙痒和整体心理健康方面发挥作用，皮肤科医生等医疗保健提供者应提高对大麻类产品的适当使用的熟悉程度。
